Verastem Inc (VSTM)

Currency in USD
5.720
-0.250(-4.19%)
Closed·
After Hours
5.550-0.170(-2.97%)
·
VSTM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VSTM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.5456.030
52 wk Range
2.1809.100
Key Statistics
Prev. Close
5.97
Open
6.03
Day's Range
5.545-6.03
52 wk Range
2.18-9.1
Volume
1.85M
Average Volume (3m)
2.45M
1-Year Change
171.36%
Book Value / Share
-0.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VSTM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.250
Upside
+166.61%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Verastem Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Verastem Inc Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem Inc SWOT Analysis


Oncology Breakthrough
Verastem's FDA-approved Av-Fak for KRAS-mutant LGSOC marks its transition to a commercial-stage company, positioning it as a key player in targeted cancer therapies
Market Access Strategy
Pursuit of NCCN guideline listing could expand Av-Fak's reach beyond KRAS-mutant LGSOC, potentially eliminating KRAS testing requirements and boosting adoption rates
Pipeline Potential
VS-7375, targeting KRAS G12D mutation, shows promise in expanding Verastem's oncology portfolio beyond LGSOC, with Phase I data eagerly anticipated at upcoming ASCO meeting
Financial Outlook
Analysts set $16 price target, reflecting optimism despite -$131M EBITDA. Strong liquidity position with 3.5 current ratio supports growth initiatives and pipeline development
Read full SWOT analysis

Compare VSTM to Peers and Sector

Metrics to compare
VSTM
Peers
Sector
Relationship
P/E Ratio
−2.1x−3.4x−0.5x
PEG Ratio
−0.12−0.170.00
Price/Book
−9.7x2.1x2.6x
Price / LTM Sales
31.4x10.0x3.3x
Upside (Analyst Target)
134.5%66.9%42.8%
Fair Value Upside
Unlock10.6%6.5%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.250
(+166.61% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.96 / -0.92
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VSTM Income Statement

People Also Watch

177.49
IQV
-3.50%
25.21
CNC
-2.63%
3.60
ALT
-1.91%
161.71
CRCL
+5.05%
83.12
OKLO
-1.16%

FAQ

What Stock Exchange Does Verastem Trade On?

Verastem is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Verastem?

The stock symbol for Verastem is "VSTM."

What Is the Verastem Market Cap?

As of today, Verastem market cap is 315.68M.

What Is Verastem's Earnings Per Share (TTM)?

The Verastem EPS (TTM) is -3.50.

From a Technical Analysis Perspective, Is VSTM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Verastem Stock Split?

Verastem has split 1 times.

How Many Employees Does Verastem Have?

Verastem has 78 employees.

What is the current trading status of Verastem (VSTM)?

As of 06 Aug 2025, Verastem (VSTM) is trading at a price of 5.72, with a previous close of 5.97. The stock has fluctuated within a day range of 5.55 to 6.03, while its 52-week range spans from 2.18 to 9.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.